NEW YORK, Jan. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (NASDAQ: XRAY).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

The investigation concerns whether Dentsply Sirona and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action] 

On December 31, 2020, Dentsply paid $1.04 billion in cash to acquire Byte, a manufacturer of clear dental aligners. On October 24, 2024, Dentsply announced the "voluntary suspension of sales and marketing of its Byte Aligners and Impression Kits while the Company conducts a review of certain regulatory requirements related to these products." The same day, in a filing with the U.S. Securities and Exchange Commission, Dentsply claimed that the suspension of Byte sales and marketing was a "precautionary measure", while disclosing that it "expects to record non-cash charges for the impairment of goodwill within the range of $450-$550 million" for its Orthodontic and Implant Solutions segment, with the decline in fair value for the Orthodontic Aligner Solutions reporting unit "driven primarily by adverse impacts from recent state regulatory trends pertaining to the Company's direct-to-consumer aligner business."

On this news, Dentsply's stock price fell $1.10 per share, or more than 4%, to close at $23.31 per share on October 25, 2024.

Then, on November 7, 2024, Dentsply reported its financial results for the third quarter of 2024, disclosing that it had "recorded a non-cash charge for the impairment of goodwill of ($495) million net of tax within the Orthodontic and Implant Solutions segment" and had revised its 2024 outlook, with expected organic sales of "(3.5%) to (2.5%) (previously (1%) to flat)" and adjusted earnings-per-share of "$1.82 to $1.86 (previously $1.96 to $2.02)." On a subsequent conference call to discuss these results, Dentsply's Chief Executive Officer disclosed that the Company was considering the "discontinuation of some or all of [Byte's] business."

On this news, Dentsply's stock price fell $6.72 per share, or more than 28%, to close at $17.26 per share on November 7, 2024.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

Attorney advertising. Prior results do not guarantee similar outcomes.  

CONTACT:

Danielle Peyton

Pomerantz LLP

dpeyton@pomlaw.com

646-581-9980 ext. 7980

View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-dentsply-sirona-inc---xray-302360927.html

SOURCE Pomerantz LLP